Can a light bulb dial down chronic pain?

NCT ID NCT07825792

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 17, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

Researchers at the University of North Carolina at Chapel Hill are testing whether daily exposure to S-cone stimulating colored light can reduce pain severity and pain sensitivity in adults with fibromyalgia or chronic widespread pain and fatigue. Participants use programmed light bulbs at home for 2 hours each morning over 7 days, then switch to equal-energy white light after a 1-week break. The trial measures how many participants complete the sessions and surveys, and tracks changes in pain intensity, interference, and sensitivity. This pilot crossover study aims to see if the approach is feasible and worth testing in a larger trial.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
S-cone stimulating chromatic light delivered through programmed light bulbs
What this could lead to
If the light approach works, it could offer a low-cost, at-home way to ease pain for people with fibromyalgia or chronic widespread pain. It might also point researchers toward how specific wavelengths of light affect the nervous system.
What could go wrong
This is a small pilot study with 40 participants, so any signal may be too weak or too variable to confirm a real benefit. Light therapy may not outperform the comparison white light, and participants might notice which light they receive despite blinding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults ≥ 18 years of age. * Individuals who have been diagnosed with fibromyalgia or suffer from chronic widespread pain and fatigue. * An average pain severity ≥4 on the 0-10 NRS over the month prior to enrollment. * Pain symptoms present for 3 months or longer. * Pain must be present in 4 out of 5 body regions. * A score of ≥7 on the Widespread pain index (WPI) and ≥5 on the symptom severity scale (SSS), or 4-6 on the WPI and ≥9 on the SSS in the 2016 Fibromyalgia Questionnaire. * Willingness to adjust light levels in home environment so that the illumination (measured in lux) provided by the light bulbs is twice the ambient room illumination (also measured in lux). * Willingness to use study lightbulbs for 2 consecutive hours a day for 7 consecutive days according to study specifications for both conditions (total of 14 days using lightbulbs) * Alert and oriented, and able to provide informed consent * Ability to read and speak English to complete validated questionnaires. Exclusion Criteria: * Vision disorders or conditions resulting in severe vision impairment or blindness * Individuals with self-report of color blindness, uveitis or cataracts. * Prisoner Status * Pregnancy * History of photosensitivity or sensitivity to scintillating (mildly flickering) light. * History of seizure disorder. * Individuals living in households with people who have a history of seizure disorders. * Analgesic treatment plan changes anticipated in the next 3 months (surgery, analgesic medication changes, injections, pain procedures, etc.). * Other history or condition that would, in the investigator's judgment, indicate that the individual would highly likely be non-compliant with the study or unsuitable for the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fibromyalgia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

agnosia fibromyalgia Musculoskeletal Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina, 27514, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.